Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for NanoViricides, Inc. (NNVC : AMEX)
 
 • Company Description   
NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development of drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides, Inc. is headquartered in West Haven, Connecticut.

Number of Employees: 7

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.41 Daily Weekly Monthly
20 Day Moving Average: 228,166 shares
Shares Outstanding: 16.07 (millions)
Market Capitalization: $22.66 (millions)
Beta: 0.88
52 Week High: $2.55
52 Week Low: $0.94
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.62% -10.12%
12 Week 6.01% -10.83%
Year To Date -1.40% -7.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 Controls Drive
-
Shelton,CT 06484
USA		 ph: 203-937-6137
fax: 203-859-5095		 adiwan@nanoviricides.com http://www.nanoviricides.com
 
 • General Corporate Information   
Officers
Anil Diwan - President and Executive Chairman
Meeta Vyas - Chief Financial Officer
Brian Zucker - Director
Makarand Jawadekar - Director
Theodore Rokita - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 630087302
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 09/26/25
Share - Related Items
Shares Outstanding: 16.07
Most Recent Split Date: 9.00 (0.05:1)
Beta: 0.88
Market Capitalization: $22.66 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/26/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.50
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 12.50%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -95.38
12/31/24 - -87.90
ROA
06/30/25 - -
03/31/25 - -84.28
12/31/24 - -78.69
Current Ratio
06/30/25 - -
03/31/25 - 2.27
12/31/24 - 3.44
Quick Ratio
06/30/25 - -
03/31/25 - 2.27
12/31/24 - 3.44
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.56
12/31/24 - 0.74
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©